SpectraCure AB (publ) (SPEC.ST)
SEK 3.59
(15.81%)
SEK 3.59
(15.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.96 Million SEK | 6.04% |
| 2022 | -22.26 Million SEK | -9.21% |
| 2021 | -20.43 Million SEK | -58.63% |
| 2020 | -12.88 Million SEK | -13.47% |
| 2019 | -11.35 Million SEK | -17.93% |
| 2018 | -9.46 Million SEK | -27.88% |
| 2017 | -7.52 Million SEK | -12.72% |
| 2016 | -6.23 Million SEK | -17.24% |
| 2015 | -5.68 Million SEK | -98.57% |
| 2014 | -2.87 Million SEK | 7.3% |
| 2013 | -3.09 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.38 Million SEK | 1.76% |
| 2024 Q1 | -5.62 Million SEK | -49.68% |
| 2023 FY | - SEK | 4.26% |
| 2023 Q1 | -4.57 Million SEK | 19.98% |
| 2023 Q3 | -3.92 Million SEK | 30.01% |
| 2023 Q2 | -5.6 Million SEK | -22.46% |
| 2023 Q4 | -6.02 Million SEK | -53.48% |
| 2022 Q1 | -5.48 Million SEK | -5.46% |
| 2022 Q3 | -4.84 Million SEK | 29.66% |
| 2022 Q4 | -5.72 Million SEK | -18.11% |
| 2022 FY | - SEK | -9.21% |
| 2022 Q2 | -6.88 Million SEK | -25.55% |
| 2021 Q4 | -5.2 Million SEK | -7.42% |
| 2021 Q3 | -4.84 Million SEK | 22.79% |
| 2021 Q2 | -6.27 Million SEK | -52.07% |
| 2021 Q1 | -4.12 Million SEK | -8.02% |
| 2021 FY | - SEK | -58.63% |
| 2020 Q2 | -4.19 Million SEK | -33.83% |
| 2020 Q4 | -3.81 Million SEK | -119.49% |
| 2020 FY | - SEK | -13.47% |
| 2020 Q1 | -3.13 Million SEK | -2.79% |
| 2020 Q3 | -1.73 Million SEK | 58.53% |
| 2019 FY | - SEK | -17.93% |
| 2019 Q4 | -3.04 Million SEK | -34.1% |
| 2019 Q3 | -2.27 Million SEK | 35.26% |
| 2019 Q2 | -3.51 Million SEK | -39.27% |
| 2019 Q1 | -2.52 Million SEK | 24.36% |
| 2018 Q4 | -3.33 Million SEK | -76.72% |
| 2018 Q1 | -16 Thousand SEK | 99.31% |
| 2018 Q2 | -4.39 Million SEK | -27350.0% |
| 2018 Q3 | -1.88 Million SEK | 57.06% |
| 2018 FY | - SEK | -27.88% |
| 2017 Q1 | -1.75 Million SEK | -27.91% |
| 2017 FY | - SEK | -12.72% |
| 2017 Q2 | -2.05 Million SEK | -16.97% |
| 2017 Q3 | -1.4 Million SEK | 31.44% |
| 2017 Q4 | -2.31 Million SEK | -64.04% |
| 2016 Q3 | -1.53 Million SEK | 21.27% |
| 2016 Q1 | -1.29 Million SEK | 30.71% |
| 2016 Q4 | -1.37 Million SEK | 10.62% |
| 2016 FY | - SEK | -17.24% |
| 2016 Q2 | -1.95 Million SEK | -51.03% |
| 2015 Q1 | 23.38 Thousand SEK | 101.72% |
| 2015 Q4 | -1.86 Million SEK | -50.39% |
| 2015 Q3 | -1.23 Million SEK | 46.33% |
| 2015 Q2 | -2.3 Million SEK | -9976.23% |
| 2015 FY | - SEK | -98.57% |
| 2014 FY | - SEK | 7.3% |
| 2014 Q1 | -287.71 Thousand SEK | 0.0% |
| 2014 Q2 | -292.62 Thousand SEK | -1.71% |
| 2014 Q3 | -750.74 Thousand SEK | -156.56% |
| 2014 Q4 | -1.35 Million SEK | -80.97% |
| 2013 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 72.811% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 105.091% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 105.091% |
| Arcoma AB | 6.24 Million SEK | 435.611% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 76.696% |
| BICO Group AB (publ) | 322.3 Million SEK | 106.506% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 131.781% |
| CellaVision AB (publ) | 207.24 Million SEK | 110.118% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 69.346% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 24.958% |
| C-Rad AB (publ) | 48.9 Million SEK | 142.878% |
| Duearity AB (publ) | -24.77 Million SEK | 15.376% |
| Dignitana AB (publ) | -264 Thousand SEK | -7842.803% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 76.09% |
| Getinge AB (publ) | 5.92 Billion SEK | 100.354% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 68.819% |
| Iconovo AB (publ) | -35.33 Million SEK | 40.657% |
| Integrum AB (publ) | 8.76 Million SEK | 339.33% |
| Luxbright AB (publ) | -23.86 Million SEK | 12.141% |
| Mentice AB (publ) | 28.87 Million SEK | 172.625% |
| OssDsign AB (publ) | -122.02 Million SEK | 82.815% |
| Paxman AB (publ) | 31.22 Million SEK | 167.146% |
| Promimic AB (publ) | -3.68 Million SEK | -469.191% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 86.068% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 59.542% |
| ScandiDos AB (publ) | -13.35 Million SEK | -57.001% |
| Sectra AB (publ) | 615.06 Million SEK | 103.409% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 59.421% |
| Senzime AB (publ) | -118.82 Million SEK | 82.353% |
| Stille AB | 56.04 Million SEK | 137.417% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 99.342% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 116.567% |